Ausgabe 6/2012
Inhalt (14 Artikel)
High-dose etoposide in allogeneic stem cell transplantation
Øystein Bruserud, Håkon Reikvam, Astrid Olsnes Kittang, Aymen Bushra Ahmed, Tor Henrik Anderson Tvedt, Malvin Sjo, Kimberley Joanne Hatfield
Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer
Takayuki Shiroyama, Takashi Kijima, Kiyoshi Komuta, Suguru Yamamoto, Seigo Minami, Yoshitaka Ogata, Kouhei Okafuji, Fumio Imamura, Tomonori Hirashima, Isao Tachibana, Ichiro Kawase, Atsushi Kumanogoh
Phase I study of nelfinavir in liposarcoma
Janet Pan, Michelle Mott, Bixin Xi, Ernestine Hepner, Min Guan, Kristen Fousek, Rachel Magnusson, Raechelle Tinsley, Frances Valdes, Paul Frankel, Timothy Synold, Warren A. Chow
Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro
Chongmei Huang, Xiaoxia Hu, Libing Wang, Shuqing Lü, Hui Cheng, Xianmin Song, Jianmin Wang, Jianmin Yang
Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models
Daniela Meco, Angela Maria Di Francesco, Gabriella Cusano, Federica Bucci, Filomena Pierri, Valentina Patriarca, Anna Rita Torella, Claudio Pisano, Riccardo Riccardi
Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment
L. A. Devriese, P. O. Witteveen, S. Marchetti, M. Mergui-Roelvink, L. Reyderman, J. Wanders, A. Jenner, G. Edwards, J. H. Beijnen, E. E. Voest, J. H. M. Schellens
6-gingerol ameliorated doxorubicin-induced cardiotoxicity: role of nuclear factor kappa B and protein glycation
Wesam M. El-Bakly, Manal L. Louka, Ali M. El-Halawany, Mona F. Schaalan
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy
Michael J. Pishvaian, Rebecca Slack, Eunice Y. Koh, Jan H. Beumer, Marion L. Hartley, Ion Cotarla, John Deeken, Aiwu Ruth He, Jimmy Hwang, Shakun Malik, Kashif Firozvi, Minetta Liu, Beth Elston, Sandy Strychor, Merrill J. Egorin, John L. Marshall
Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas
Rinat Bernstein-Molho, Yehuda Kollender, Josephine Issakov, Jacob Bickels, Shlomo Dadia, Gideon Flusser, Isaac Meller, Ronit Sagi-Eisenberg, Ofer Merimsky
Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials
Man-Tang Qiu, Xiang-Xiang Ding, Jing-Wen Hu, Hong-Ya Tian, Rong Yin, Lin Xu
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
Andrew H. Ko, Thach-Giao Truong, Emily Kantoff, Kimberly A. Jones, Elizabeth Dito, Anna Ong, Margaret A. Tempero
Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer
M. Provencio, C. Camps, M. Cobo, R. De las Peñas, B. Massuti, R. Blanco, V. Alberola, U. Jimenez, J. R. Delgado, F. Cardenal, M. Tarón, J. L. Ramírez, A. Sanchez, R. Rosell
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies
Da Zhang, Monica Mita, Geoffrey I. Shapiro, Jennifer Poon, Karen Small, Anjela Tzontcheva, Bhavna Kantesaria, Yali Zhu, Rajat Bannerji, Paul Statkevich
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer
Marta Lucchetta, Sara Lonardi, Francesca Bergamo, Paola Alberti, Roser Velasco, Andreas A. Argyriou, Chiara Briani, Jordi Bruna, Marina Cazzaniga, Diego Cortinovis, Guido Cavaletti, Haralabos P. Kalofonos